99 related articles for article (PubMed ID: 15361183)
41. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
42. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
43. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
44. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
[TBL] [Abstract][Full Text] [Related]
45. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
46. Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer.
Nicoletto MO; Tumolo S; Sorio R; Cima G; Endrizzi L; Nascimben O; Vinante O; Artioli G; Donach M; Cartei G;
Int J Gynecol Cancer; 2007; 17(5):986-92. PubMed ID: 17316364
[TBL] [Abstract][Full Text] [Related]
47. Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma.
Sorbe B
Int J Gynecol Cancer; 2004; 14(5):788-93. PubMed ID: 15361185
[TBL] [Abstract][Full Text] [Related]
48. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
Nicholson S; Gooden CS; Hird V; Maraveyas A; Mason P; Lambert HE; Meares CF; Epenetos AA
Oncol Rep; 1998; 5(1):223-6. PubMed ID: 9458326
[TBL] [Abstract][Full Text] [Related]
49. Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.
Lee CK; Pires de Miranda M; Ledermann JA; Ruiz de Elvira MC; Nelstrop AE; Lambert HE; Rustin GJ; Trask CW
Eur J Cancer; 1999 May; 35(5):727-32. PubMed ID: 10505032
[TBL] [Abstract][Full Text] [Related]
50. Predictive factors for long-term survival in patients with advanced ovarian cancer.
Krag KJ; Canellos GP; Griffiths CT; Knapp RC; Parker LM; Welch WR; Klatt M; Andersen J
Gynecol Oncol; 1989 Jul; 34(1):88-93. PubMed ID: 2525510
[TBL] [Abstract][Full Text] [Related]
51. Intervention debulking surgery in advanced epithelial ovarian cancer.
Redman CW; Warwick J; Luesley DM; Varma R; Lawton FG; Blackledge GR
Br J Obstet Gynaecol; 1994 Feb; 101(2):142-6. PubMed ID: 8305389
[TBL] [Abstract][Full Text] [Related]
52. An audit of surgical treatment of ovarian cancer in a metropolitan health region. Association of Obstetricians and Gynaecologists of the North East Thames Region.
Hudson CN; Potsides P; Curling OM
J R Soc Med; 1991 Apr; 84(4):206-9. PubMed ID: 2027145
[TBL] [Abstract][Full Text] [Related]
53. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies.
Edmonson JH; Su J; Krook JE
Cancer; 1993 Jan; 71(2 Suppl):615-7. PubMed ID: 8420684
[TBL] [Abstract][Full Text] [Related]
54. Advanced small cell carcinoma of the ovary in a pediatric patient with long-term survival and review of the literature.
Sholler GL; Luks F; Mangray S; Meech SJ
J Pediatr Hematol Oncol; 2005 Mar; 27(3):169-72. PubMed ID: 15750452
[TBL] [Abstract][Full Text] [Related]
55. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience.
Thigpen T; Brady MF; Omura GA; Creasman WT; McGuire WP; Hoskins WJ; Williams S
Cancer; 1993 Jan; 71(2 Suppl):606-14. PubMed ID: 8420683
[TBL] [Abstract][Full Text] [Related]
56. The outlook for women with borderline epithelial tumours of the ovary.
Tasker M; Langley FA
Br J Obstet Gynaecol; 1985 Sep; 92(9):969-73. PubMed ID: 4041401
[TBL] [Abstract][Full Text] [Related]
57. Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion.
Bertelsen K; Andersen JE
Int J Gynecol Cancer; 1994 May; 4(3):180-187. PubMed ID: 11578404
[TBL] [Abstract][Full Text] [Related]
58. What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods.
Bertelsen K; Kruhøffer A
Int J Gynecol Cancer; 1995 Mar; 5(2):148-155. PubMed ID: 11578470
[TBL] [Abstract][Full Text] [Related]
59. Current concepts in cancer: ovary--treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors.
Dembo AJ; Bush RS
Int J Radiat Oncol Biol Phys; 1982 May; 8(5):893-7. PubMed ID: 7107423
[No Abstract] [Full Text] [Related]
60. Comment on 'Age of enlightenment: long-term effects of outdoor aesthetic lights on bats in churches'.
Onkelinx T
R Soc Open Sci; 2017 Nov; 4(11):171312. PubMed ID: 29291116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
